New drug combo shows early promise in Hard-to-Treat cancers
NCT ID NCT05162755
First seen Nov 05, 2025
Summary
This early-phase trial tested a new drug called S095029, alone and combined with another drug (Sym021), in 41 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and side effects. The study was stopped early for business reasons, not due to safety concerns, so we don't yet know if the combination works well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Princess Margaret Cancer Centre
Toronto, Canada
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
The START Center for Cancer Care
San Antonio, Texas, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
S095029 (a drug that targets NKG2A) and Sym021 (a drug that targets PD-1)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 41 participants, so it is primarily testing safety, not effectiveness. The expansion part was stopped early for business reasons, so results are limited.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.